Merck handed $200m in Gilead hepatitis C row

Gilead has been ordered to pay Merck $200 million in damages following a trial that found it had infringed patents covering hepatitis C treatments.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck claims hepatitis C patent win

23 March 2016 A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

3 May 2016 A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Americas

Judge overturns $200m award in Gilead v Merck

9 June 2016 A US court has overturned an earlier ruling in which Merck was awarded $200 million in damages for patent infringement after finding that the pharmaceutical company had engaged in misconduct.

More on this story

Americas

Merck claims hepatitis C patent win

23 March 2016 A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

3 May 2016 A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Americas

Judge overturns $200m award in Gilead v Merck

More on this story

Americas

Merck claims hepatitis C patent win

23 March 2016 A US court has upheld the validity of two patents owned by Merck in the pharmaceutical company’s dispute with drug maker Gilead centring on hepatitis C treatments.

Americas

Gilead v Merck hepatitis C dispute rocked by new allegation

3 May 2016 A judge assessing a patent dispute between Merck and Gilead centring on hepatitis C treatments has allowed Gilead to submit new evidence of jurors allegedly being misled.

Americas

Judge overturns $200m award in Gilead v Merck